西鲁库单抗单药治疗与阿达木单抗单药治疗在生物制剂初治活动性类风湿关节炎患者中的疗效与安全性比较(SIRROUND-H):一项随机、双盲、平行组、多国、52周、3期研究
该随机双盲3期研究在生物制剂初治的活动性类风湿关节炎患者中比较西鲁库单抗单药与阿达木单抗单药,第24周西鲁库单抗100mg每2周组DAS28(ESR)改善显著优于阿达木单抗40mg每2周组,50mg每4周组亦显著优于阿达木单抗,但ACR50应答率三组相近,安全性特征与抗白介素-6受体抗体一致。
要点
- 第24周西鲁库单抗100mg每2周组DAS28(ESR)较基线变化-2.96,优于阿达木单抗组的-2.19(P<0.001)。
- 第24周西鲁库单抗50mg每4周组DAS28(ESR)较基线变化-2.58,亦优于阿达木单抗组(P=0.013)。
- 第24周ACR50应答率西鲁库单抗100mg组35.3%、50mg组26.9%,与阿达木单抗组31.7%相近。
核心结论
- 西鲁库单抗单药治疗在DAS28(ESR)改善上优于阿达木单抗单药,但ACR50应答率相似。
研究设计与样本
- 随机、双盲、平行组、多国、52周、3期研究,纳入生物制剂初治的活动性类风湿关节炎患者,对甲氨蝶呤应答不足、不耐受或不适用。
- 患者随机接受皮下西鲁库单抗100mg每2周(n=187)、西鲁库单抗50mg每4周(n=186)或阿达木单抗40mg每2周(n=186)。
- 主要终点为第24周DAS28(ESR)较基线变化和ACR50应答率,按序贯顺序检验。
主要发现
- 第24周DAS28(ESR)较基线平均(SD)变化:西鲁库单抗100mg每2周组-2.96(1.580) vs 阿达木单抗40mg每2周组-2.19(1.437),P<0.001。
- 第24周DAS28(ESR)较基线平均(SD)变化:西鲁库单抗50mg每4周组-2.58(1.524) vs 阿达木单抗组,P=0.013。
- 第24周ACR50应答率:西鲁库单抗100mg组35.3%、50mg组26.9%,与阿达木单抗组31.7%相近。
- 西鲁库单抗的安全性特征与抗白介素-6受体抗体观察到的特征一致。
- 西鲁库单抗对注射部位反应发生率呈剂量相关效应。
关键数值与推荐
- 主要终点第24周DAS28(ESR)较基线变化和ACR50应答率按序贯顺序检验。
临床怎么用
- 原文未据此给出推荐。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
OBJECTIVE: This randomised, double-blind, parallel-group, phase 3 study compared monotherapy with sirukumab, an anti-interleukin-6 cytokine monoclonal antibody, with adalimumab monotherapy in patients with rheumatoid arthritis (RA). METHODS: Biologic-naïve patients with active RA who were inadequate responders or were intolerant to, or inappropriate for, methotrexate were randomised to subcutaneous sirukumab 100 mg every 2 weeks (n=187), sirukumab 50 mg every 4 weeks (n=186) or adalimumab 40 mg every 2 weeks (n=186). Primary endpoints at week 24 were change from baseline in Disease Activity Score in 28 joints (DAS28) using erythrocyte sedimentation rate (ESR) and proportion of patients achieving an American College of Rheumatology (ACR) 50 response; these endpoints were tested in sequential order. This study is registered at EudraCT (number: 2013-001417-32) and ClinicalTrials.gov (number: NCT02019472). RESULTS: Significantly greater improvements from baseline in mean (SD) DAS28 (ESR) were observed at week 24 with sirukumab 100 mg every 2 weeks (-2.96 (1.580)) versus adalimumab 40 mg every 2 weeks (-2.19 (1.437); P<0.001). Sirukumab 50 mg every 4 weeks also showed significantly greater improvement from baseline at week 24 in DAS28 (ESR) (-2.58 (1.524)) compared with adalimumab (P=0.013). The ACR50 response rates with the 100 mg (35.3%) and 50 mg (26.9%) doses of sirukumab were comparable to that with adalimumab (31.7%) at week 24. The safety profile of sirukumab was consistent with that observed with anti-interleukin-6 receptor antibodies. A dose-related effect on the incidence of injection-site reactions was observed with sirukumab. CONCLUSION: Sirukumab monotherapy showed greater improvements in DAS28 (ESR), but similar ACR50 response rates, versus adalimumab monotherapy.
引用
- Taylor PC, Schiff MH, Wang Q, et al. Efficacy and safety of monotherapy with sirukumab compared with adalimumab monotherapy in biologic-naïve patients with active rheumatoid arthritis (SIRROUND-H): a randomised, double-blind, parallel-group, multinational, 52-week, phase 3 study. Ann Rheum Dis. 2018. PMID: 29483080. doi:10.1136/annrheumdis-2017-212496
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。